Sort by
Refine Your Search
-
, religion or ethnic background are encouraged to apply. As DTU works with research in critical technology, which is subject to special rules for security and export control, open-source background checks may
-
analysis and future experiments. Dr Francavilla’s team is funded by the Novo Nordisk Foundation and LEO Foundation and focuses on regulatory mechanisms of cell signalling in several cellular models. The team
-
to special rules for security and export control, open-source background checks may be conducted on qualified candidates for the position. DTU Compute – Department of Mathematics and Computer
-
efforts have been dedicated to developing prediction models governing TCR interactions. However, overall the accuracy is limited, and characterizing and predicting these interactions remains a significant
-
models, in vivo cancer xenotransplant mice models (with according to certifications), and assessment of therapeutics in preclinical cancer models. Besides the necessity of high motivation and excellent
-
molecules. Large efforts have been dedicated to developing prediction models governing TCR interactions. However, overall the accuracy is limited, and characterizing and predicting these interactions remains
-
. Co-supervising PhD & MSc students, particularly those working in electrophysiology and computational modelling. Developing an online tinnitus test battery and database Stratify tinnitus phenotypes
-
interest and experience in semi-analytical models and submillimetre selected galaxies, who are interested in doing research in collaboration with senior researcher Bitten Gullberg and her group as part of
-
projections to generate 3-dimensikonal models and descriptions of motility patterns, swimming gaits, prey encounter, and prey handling Perform experiments to quantify foraging capacity and prey selectivity in
-
The Technical University of Denmark (DTU), the The Novo Nordisk Foundation Center for Stem Cell Medicine (renew) at University of Copenhagen, and Bioneer A/S that aims at developing new in vitro disease models